Becton, Dickinson Aktie
WKN: 857675 / ISIN: US0758871091
|
03.11.2025 13:37:50
|
BD Receives U.S. FDA, EU Clearance For Enteric Bacterial Panels On BD COR System
(RTTNews) - Becton, Dickinson and Company (BDX), a medical technology firm, on Monday said it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for use on the BD COR System.
The BD COR System automates molecular lab workflows, supporting up to 1,650 tests and delivering up to 1,000 sample results in 24 hours with barcode-driven traceability and remote system management.
The BD EBP panels detect a broad range of enteric bacterial pathogens, including Salmonella spp., Campylobacter spp., Shigella spp./Enteroinvasive Escherichia coli (EIEC), and Shiga toxin-producing Escherichia coli (STEC). The panels use advanced Polymerase Chain Reaction (PCR) technology to streamline testing for a broad range of gastrointestinal (GI) bacterial pathogens from a single stool swab sample.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Becton, Dickinson & Co. (BD)mehr Nachrichten
Analysen zu Becton, Dickinson & Co. (BD)mehr Analysen
Aktien in diesem Artikel
| Becton, Dickinson & Co. (BD) | 153,70 | -1,54% |
|